Comparison of HCV-positive with HCV-negative patients
| . | HCV-positive (n = 131), n (%) . | HCV-negative (n = 422), n (%) . | P . |
|---|---|---|---|
| Median age, y (range) | 70.4 (42-86) | 64.3 (20-92) | < .001 |
| Sex, male/female | 79/52 | 228/194 | .21 |
| LDH > normal | 81 (62) | 196 (46) | .002 |
| PS > 1 | 16 (12) | 40 (9) | .47 |
| Stage | .48 | ||
| I | 28 (21) | 92 (22) | |
| II | 39 (30) | 130 (31) | |
| III | 20 (15) | 84 (20) | |
| IV | 44 (34) | 116 (27) | |
| Extranodal sites > 1 | 36 (27) | 75 (18) | .02 |
| IPI: H/I, H | 53 (40) | 139 (33) | .01 |
| BM involvement | 12 (9) | 38 (9) | .96 |
| Spleen involvement | 24 (18) | 35 (8) | .001 |
| Liver involvement | 12 (9) | 25 (6) | .20 |
| t-DLBCL | 5 (4) | 11 (3) | .82 |
| FL | 3 | 5 | |
| MZBCL | 2 | 6 | |
| HBsAb-positive | 7/59 (12) | 13/135 (10) | .24 |
| HBcAb-positive | 11/22 (50) | 9/57 (16) | .03 |
| Treatment | .12 | ||
| RCHOP | 96 (73) | 339 (80) | |
| RTHPCOP | 31 (24) | 71 (17) | |
| RCEOP | 4 (3) | 12 (3) | |
| Baseline transaminase | .48 | ||
| Grade 0-1 | 122 (93) | 415 (98) | |
| Grade 2 | 7 (5) | 3 (1) | |
| Grade 3 | 2 (2) | 4 (1) | |
| Outcome of patients | |||
| Died of lymphoma | 14 (11) | 45 (11) | .87 |
| Died of hepatic failure | 6 (5) | 1 (0.2) | < .001 |
| Died of other causes | 4 (3) | 7 (2) | .76 |
| Hepatic toxicity | |||
| Grade 3-4 | 36 (27) | 13 (3) | < .001 |
| . | HCV-positive (n = 131), n (%) . | HCV-negative (n = 422), n (%) . | P . |
|---|---|---|---|
| Median age, y (range) | 70.4 (42-86) | 64.3 (20-92) | < .001 |
| Sex, male/female | 79/52 | 228/194 | .21 |
| LDH > normal | 81 (62) | 196 (46) | .002 |
| PS > 1 | 16 (12) | 40 (9) | .47 |
| Stage | .48 | ||
| I | 28 (21) | 92 (22) | |
| II | 39 (30) | 130 (31) | |
| III | 20 (15) | 84 (20) | |
| IV | 44 (34) | 116 (27) | |
| Extranodal sites > 1 | 36 (27) | 75 (18) | .02 |
| IPI: H/I, H | 53 (40) | 139 (33) | .01 |
| BM involvement | 12 (9) | 38 (9) | .96 |
| Spleen involvement | 24 (18) | 35 (8) | .001 |
| Liver involvement | 12 (9) | 25 (6) | .20 |
| t-DLBCL | 5 (4) | 11 (3) | .82 |
| FL | 3 | 5 | |
| MZBCL | 2 | 6 | |
| HBsAb-positive | 7/59 (12) | 13/135 (10) | .24 |
| HBcAb-positive | 11/22 (50) | 9/57 (16) | .03 |
| Treatment | .12 | ||
| RCHOP | 96 (73) | 339 (80) | |
| RTHPCOP | 31 (24) | 71 (17) | |
| RCEOP | 4 (3) | 12 (3) | |
| Baseline transaminase | .48 | ||
| Grade 0-1 | 122 (93) | 415 (98) | |
| Grade 2 | 7 (5) | 3 (1) | |
| Grade 3 | 2 (2) | 4 (1) | |
| Outcome of patients | |||
| Died of lymphoma | 14 (11) | 45 (11) | .87 |
| Died of hepatic failure | 6 (5) | 1 (0.2) | < .001 |
| Died of other causes | 4 (3) | 7 (2) | .76 |
| Hepatic toxicity | |||
| Grade 3-4 | 36 (27) | 13 (3) | < .001 |
LDH indicates lactate dehydrogenase; PS, ECOG performance status; H/I, high-intermediate; H, high; BM, bone marrow; t-DLBCL, transformed diffuse large B-cell lymphoma; FL, follicular lymphoma; MZBCL, marginal zone B-cell lymphoma; HBsAb, antibody to hepatitis B surface antigen; HBcAb, antibody to hepatitis B core antigen; RCHOP, rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone; RTHPCOP, rituximab plus cyclophosphamide, teralbicin, vincristine, and prednisone; and RCEOP, rituximab plus cyclophosphamide, epirubicin, vincristine, and prednisone. Grade was defined by the National Cancer Institute of Canada criteria.